Skip to content
Clinical Trials – home

Fondazione IRCCS Policlinico San Matteo

Verified siteinfo

Italy Viale Camillo Golgi 19, 27100 Pavia, Italy

  • 168 trials recruiting
  • Non-small cell lung cancer · Acute myeloid leukaemia · Colitis ulcerative
  • Adults and children

About Specializations

Fondazione IRCCS Policlinico San Matteo in Pavia, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Acute myeloid leukaemia, Colitis ulcerative, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular and Metabolic Research

At Fondazione IRCCS Policlinico San Matteo in Pavia, clinical trials in cardiovascular diseases and nutritional and metabolic disorders focus on major conditions such as atrial fibrillation, acute myocardial infarction, heart failure, atherosclerotic cardiovascular disease, and hypertriglyceridemia. These studies are designed to test new treatments, reduce serious cardiovascular events, and improve long-term disease control.

  • New approaches for preventing stroke and other embolic events in atrial fibrillation
  • Treatments aimed at lowering the risk of heart attack and recurrent cardiovascular events
  • Studies targeting heart failure, myocarditis, and transthyretin-mediated amyloid cardiomyopathy
  • Research on controlling high triglycerides and broader metabolic risk

This area also includes work on improving outcomes in patients with established cardiovascular disease through safer and more effective therapies.

Oncology and Hematology Trials

A large share of the research portfolio centers on neoplasms and hemic and lymphatic diseases, with studies in lung cancer, renal cell carcinoma, breast cancer, melanoma, esophageal carcinoma, and blood cancers such as acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. The goal is to evaluate new cancer therapies, improve survival, and refine treatment strategies across solid tumors and hematologic malignancies.

  • Testing new treatment combinations for advanced non-small cell lung cancer and renal cancer
  • Studies in lymphoma, multiple myeloma, and myelodysplastic syndromes to improve disease control
  • Research in melanoma and breast cancer aimed at extending progression-free survival
  • Pediatric and adult trials in acute leukemia focused on better outcomes and response rates

The site’s oncology program reflects broad expertise in both solid tumors and blood cancers, supporting studies that compare new options with current standard care.

Respiratory, Allergy, and Transplant Medicine

Research in respiratory tract diseases, immune system diseases, and congenital, hereditary, and neonatal diseases includes trials for asthma, chronic obstructive pulmonary disease, bronchiectasis, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and lung transplant rejection. These studies aim to improve breathing symptoms, reduce flare-ups, and support transplant and chronic lung disease care.

  • Evaluating new options for severe asthma in children, adolescents, and adults
  • Trials in COPD and bronchiectasis to reduce exacerbations and improve daily function
  • Studies for pulmonary arterial hypertension and pulmonary fibrosis to slow disease progression
  • Research on chronic lung allograft dysfunction and lung transplant rejection

This respiratory portfolio combines symptom relief, disease modification, and long-term lung function preservation.

Autoimmune, Inflammatory, and Infectious Disease Research

The site also conducts trials in immune system diseases, skin and connective tissue diseases, digestive system diseases, and virus diseases. Key areas include ulcerative colitis, polymyalgia rheumatica, systemic sclerosis-associated interstitial lung disease, chronic spontaneous urticaria, HIV-1 infection, and mpox virus disease. These studies are aimed at improving symptom control, reducing inflammation, and assessing treatment safety and effectiveness.

  • New therapies for ulcerative colitis and other inflammatory bowel conditions
  • Studies in polymyalgia rheumatica, systemic sclerosis, and related lung involvement
  • Research on chronic spontaneous urticaria to better control persistent itching and hives
  • Trials in HIV-1 and mpox focused on treatment effectiveness and safety

Together, these studies show a strong emphasis on immune-mediated conditions and selected infectious diseases, with a focus on practical improvements in patient care.

Eye, Skin, and Musculoskeletal Conditions

Additional research at Fondazione IRCCS Policlinico San Matteo includes eye diseases, musculoskeletal diseases, and related inflammatory conditions such as open-angle glaucoma, ocular hypertension, skin and connective tissue disorders, and polymyalgia rheumatica. The aim is to improve disease monitoring, preserve function, and evaluate therapies that may offer better control than current options.

  • Studies to reduce pressure-related damage in glaucoma and ocular hypertension
  • Research in polymyalgia rheumatica to achieve sustained remission
  • Trials addressing inflammatory conditions that affect mobility and quality of life
  • Work on better treatment options for chronic eye disease management

This part of the portfolio adds breadth to the site’s research profile, extending beyond major internal medicine and cancer programs.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Viale Camillo Golgi 1927100 PaviaItaly
Recruiting now
168 trials
Conditions studied
182
Partner status
Verified site

More sites in PaviaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

436 clinical trials

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.